Drugs in Dev.
Pulmonary/Respiratory Diseases
IND Enabling
United States 
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Nosis Bio Announces Development Candidate Nomination for Lead Fibrosis Program
Details : The nominated cell-targeted therapeutic selectively silences fibrotic drivers only in the pathogenic cells responsible for fibrosis disease.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
July 31, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nalmefene Hydrochloride
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Tharimmune gets FDA Feedback on NDA Path for TH104 in Opioid Exposure
Details : Tharimmune is seeking to develop TH104 for "Temporary Prophylaxis of Respiratory or Nervous System Depression in Military Personnel and Chemical Incident Responders".
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 31, 2025
Lead Product(s) : Nalmefene Hydrochloride
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : HBM-9378
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Harbour BioMed Gets NMPA IND Clearance for HBM9378 in COPD
Details : HBM9378/SKB378 (also known as WIN378), a fully human antibody targeting thymic stromal lymphopoietin (TSLP), being investigated for the treatment of chronic obstructive pulmonary disease (COPD).
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
February 04, 2025
Lead Product(s) : HBM-9378
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SKB378
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Harbour BioMed Submits IND for HBM9378 in Chronic Obstructive Pulmonary Disease
Details : HBM9378 is a fully human antibody targeting thymic stromal lymphopoietin (TSLP), being evaluated for the treatment of chronic obstructive pulmonary disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 08, 2024
Lead Product(s) : SKB378
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Briquilimab
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Jasper Receives Health Canada Clearance for Phase 1b/2a Briquilimab Study in Asthma
Details : JSP191 (briquilimab) is a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases. It is being evaluated for the treatment of Asthma.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
September 10, 2024
Lead Product(s) : Briquilimab
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Lixudebart
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Alentis Receives FDA ODD for Lixudebart to Treat Idiopathic Pulmonary Fibrosis
Details : ALE.F02 (Lixudebart) is a claudin 1 inhibitor ADC, which is currently being evaluated for the treatment of Idiopathic Pulmonary Fibrosis.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
May 29, 2024
Lead Product(s) : Lixudebart
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nintedanib Esylate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
MannKind Proceeds with Phase 1 Nintedanib Dpi Study for Pulmonary Fibrotic Diseases
Details : The inhaled therapeutic candidate MNKD-201 (nintedanib) is being evaluated in early-stage clinical trial studies for treating patients suffering from pulmonary fibrotic diseases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 30, 2024
Lead Product(s) : Nintedanib Esylate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tazarotene
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GRI-0621, a small molecule that inhibits the activity of human type 1, iNKT cells. It is being evaluated for the treatment of Idiopathic Pulmonary Fibrosis (IPF).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 27, 2023
Lead Product(s) : Tazarotene
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Pegtarazimod
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RLS-0071 is the Company’s lead dual-action complement and innate inflammatory inhibitor peptide in development for acute exacerbations of chronic obstructive pulmonary disease, and other rare and acute inflammatory diseases.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
October 24, 2023
Lead Product(s) : Pegtarazimod
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Rusalatide Acetate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Chrysalis Receives FDA Approval to Initiate Clinical Trials with Chrysalin™ (TP508)
Details : Chrysalin (rusalatide acetate) is a natural regenerative peptide that accelerates tissue repair and revascularization while modulating the inflammatory response, which is investigated for Acute Respiratory Distress Syndrome.
Product Name : Chrysalin
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
September 26, 2023
Lead Product(s) : Rusalatide Acetate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
